Differential expression of genes in microsatellite instability

A method of identifying colon tissue having microsatellite instability, comprising:

• (a) obtaining a colon tissue sample from an individual;
• (b) detecting the expression of one or more of the sequences of SEQ ID Nos 1-34, wherein colon tissue having microsatellite instability is detected if the expression of said one or more of the sequences of SEQ ID Nos 1-34 is at least 2-fold greater than that of the same sequence in a colon tissue sample known to not have microsatellite instability.

A method of determining the efficacy of a test compound for inhibiting cancer in a subject, the method comprising comparing a) the expression level of one or more nucleic acid sequences in a first biological sample from the subject wherein the sample has been exposed to the test compound, with b) the expression level of said nucleic acid sequences in a second biological sample from the subject wherein the sample has not been exposed to the test compound, said nucleic acid sequences comprising one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs:

• 1-34, wherein a change of at least two fold in the expression level of said nucleic acid sequences is an indication that the test compound is efficacious for inhibiting cancer in the subject.

A method of determining the efficacy of a therapy for inhibiting cancer in a subject, the method comprising comparing a) the expression level of one or more nucleic acid sequences in a first biological sample from the subject prior to providing at least a portion of the therapy to the subject, with b) the expression level of said nucleic acid sequences in a second biological sample from the subject following the provision of at least a portion of the therapy, said nucleic acid sequences comprising one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs:

• 1-34, wherein a change of at least two fold in the expression level of said nucleic acid sequences is an indication that the therapy is efficacious for inhibiting cancer in the subject.

A method of determining the efficacy of a test compound for inhibiting cancer in a subject, the method comprising comparing a) in a first biological sample from the subject binding between one or more polypeptide ligands that specifically bind to one or more polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs:

• 35-68 and one or more polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs:
• 35-68, wherein the sample has not been exposed to the test compound, with b) in a second biological sample from the subject, the specific binding of said polypeptide ligands and said polypeptides, wherein the sample has been exposed to the test compound, and wherein a significant change in the specific binding is an indication that the test compound is efficacious for inhibiting cancer in the subject.

A method of determining the efficacy of a therapy for inhibiting cancer in a subject, comprising comparing a) in a first biological sample from the subject prior to a treatment, binding between one or more polypeptide ligands that specifically bind to one or more polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs:

• 35-68 and one or more polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs:
• 35-68, with b) in a second biological sample from the subject following the treatment, the specific binding of said polypeptide ligands and said polypeptides, and wherein a significant change in the specific binding is an indication that the test compound is efficac for inhibiting cancer in the subject.